Generic antiretroviral drugs--will they be the answer to HIV in the developing world?
Kumarasamy
N
N
YRG Centre for AIDS Research and Education, VHS, Chennai-600113, India. Kumarasamy@yrgcare.org
D000328:Adult; D044966:Anti-Retroviral Agents / Q000008:administration & dosage* / Q000191:economics; D023241:Antiretroviral Therapy, Highly Active; D003906:Developing Countries; D004338:Drug Combinations; D016527:Drug Costs; D016568:Drugs, Generic / Q000008:administration & dosage* / Q000191:economics; D015658:HIV Infections / Q000188:drug therapy* / Q000191:economics; D015497:HIV-1; D006801:Humans; D019259:Lamivudine / Q000008:administration & dosage / Q000191:economics; D019829:Nevirapine / Q000008:administration & dosage / Q000191:economics; D012449:Safety; D018119:Stavudine / Q000008:administration & dosage / Q000191:economics; D016896:Treatment Outcome
D044966:Anti-Retroviral Agents; D004338:Drug Combinations; D016568:Drugs, Generic; D019259:Lamivudine; D019829:Nevirapine; D018119:Stavudine